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ABSTRACT
Introduction: The 1 year prevalence of depression in
adolescents is about 2%. Treatment with antidepressant
medication is not recommended for initial treatment in
young people due to concerns over high side effects,
poor efficacy and addictive potential. Evidence suggests
that cognitive behaviour therapy (CBT) is an effective
treatment for depression and is currently one of the
main treatment options recommended in adolescents.
Given the affinity young people have with information
technology they may be treated effectively, more widely
and earlier in their illness evolution using computer-
administered CBT (CCBT). Currently little is known
about the clinical and resource implications of
implementing CCBT within the National Health Service
for adolescents with low mood/depression. We aim to
establish the feasibility of running a fully powered
randomised controlled trial (RCT).
Methods and analysis: Adolescents aged 12–18 with
low mood/depression, (scoring ≥20 on the Mood and
Feelings Questionnaire (MFQ)), will be approached to
participate. Consenting participants will be randomised
to either a CCBT programme (Stressbusters) or
accessing selected websites providing information
about low mood/depression. The primary outcome
measure will be the Beck Depression Inventory (BDI).
Participants will also complete generic health measures
(EQ5D-Y, HUI2) and resource use questionnaires to
examine the feasibility of cost-effectiveness analysis.
Questionnaires will be completed at baseline, 4 and 12-
month follow-ups. Progress and risk will be monitored
via the MFQ administered at each treatment session.
The acceptability of a CCBT programme to adolescents;
and the willingness of clinicians to recruit participants
and of participants to be randomised, recruitment rates,
attrition rates and questionnaire completion rates will be
collected for feasibility analysis. We will estimate
‘numbers needed’ to plan a fully powered RCT of clinical
and cost-effectiveness.
Ethics and dissemination: The current trial protocol
received a favourable ethical opinion from Leeds
(West) Research and Ethics Committee. (Reference:
10/H1307/137).
Trial registration number: ISRCTN31219579.
INTRODUCTION
Tricyclic antidepressants have no benefit over
placebos in the treatment of adolescent
depression1 and are not recommended for
treatment in this group by the National
Institute for Health and Care Excellence
(NICE) guidelines.2 At the time of ethical
approval for this study, the European
Medicines Agency3 4 recommended that
SSRIs in general should not be used for the
treatment of depression in young people,
with the exception of fluoxetine where there
was some evidence, although limited, of its
efficacy. There are additional concerns about
the addictive potential of antidepressants
and many young people and parents would
prefer a ‘talking’ therapy in the first
instance.5 6 The argument against using
medication early is further strengthened by
the finding of a large study showing that
21% of moderate to severely depressed ado-
lescents improved with a brief psychosocial
Strengths and limitations of this study
▪ The study addresses an under-researched area
and will produce important feasibility information
to inform a fully powered randomised controlled
trial (RCT).
▪ The study explores the feasibility of using a
range of mental health and health economics
measures.
▪ Feasibility data on acceptability, completion rates
and attrition are supplemented by participant
qualitative interviews.
▪ The study explores the feasibility of various eco-
nomic analysis measures in a population of ado-
lescents with low mood.
▪ The sample of participants is obtained from only
one NHS Trust resulting in potential bias. A
future fully powered RCT will be extended to
other localities.
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intervention before being randomised between medica-
tion and treatment as usual.7 There is thus a climate of
caution about antidepressant use in general and particu-
larly in adolescents, due to evidence of poor efficacy
and high side effects. Research therefore needs to focus
on investigating the use of more acceptable and access-
ible psychosocial treatments for adolescent depression.
Reviews of cognitive behavioural therapy (CBT) for ado-
lescent depression have shown that it is effective and cur-
rently one of the main treatment options recommended
in adolescents.2 8 Trials comparing CBT to either family
therapy or supportive psychotherapy show that it is better
at both improving mood and achieving remission.9 It has
also been shown to prevent depression in high-risk adoles-
cent groups including the offspring of depressed adults.10
Since it has a low side effect profile it is an attractive alter-
native option for the treatment of adolescent depression.
However, some studies have questioned its efficacy in
young people with moderate to severe depression, ques-
tioning how powerful a treatment it is.7 11
The 1 year prevalence of depression in adolescents is
about 2%.12 An area with a population of 300 000, such
as that served by the York and Selby Community
Adolescent Mental Health Service (CAMHS), would be
expected to have at least 450 young people with depres-
sion. Delivering CBT to this number of young people is
far more resource intensive in terms of time than using
medication. Many primary care doctors are referring all
young people directly in to CAMHS rather than man-
aging them in primary care, as they are reluctant to use
medication and do not have the time or experience to
deliver psychological therapy. Most primary care counsel-
lors are not trained to counsel adolescents. This creates
an additional pressure in CAMHS. Together with other
service pressures, this leads to long waiting lists in
CAMH services in some areas. As a result, it is unlikely
that individual CBT needs can be met from existing
therapist resources.13 This therefore presents a number
of challenges to services, including demands on clinical
time, the potential development of waiting lists and
issues about prioritisation of services.
Given the affinity young people have with information
technology, it may be that young people could be
treated effectively and more widely using CCBT and at
an earlier stage in the evolution of their illness. The
Improving Access to Psychological Therapies (IAPT) pro-
gramme was introduced to improve availability of therap-
ies and specifically mentions the use of CCBT in
relation to depression. CCBT represents an alternative
form of therapy delivery, which has the potential to
enhance access to CBT and to provide a realistic alterna-
tive therapy or potentially a preventive intervention early
in the course of depressive illness. Some argue that
many adolescents, often reluctant to engage one to one
with a therapist, may be more comfortable accessing
computerised material or therapy.
CCBT comes in many forms and can be directed at a
range of conditions and age groups, but adequate
research needs to be conducted to capture this broad
range of possible new therapies. Existing research into
CCBT, which has mainly been conducted with adults with
depression, has most recently been summarised in a 2006
HTA review of clinical and cost-effectiveness.14 With
respect to depression, three commercially-produced com-
puterised packages available to the National Health
Service (NHS) were considered—Beating The Blues, Cope
and Overcoming Depression. Of these, only one adult inter-
vention, Beating The Blues, best suited to those aged 25
and over, had been evaluated in a randomised controlled
trial by its developers.13 An internet package, MoodGYM,
used with adults has been evaluated in a general adoles-
cent population but 70% of young people did not com-
plete the programme.15
The CCBT package Stressbusters, (developed by a team
from Manchester, The Institute of Psychiatry, London
and Australia), combining expertise in CBT and
computer-based delivery was specifically developed for
use in an adolescent population. The programme has
had a very encouraging case series where the programme
was successfully used with over 30 adolescents, 70% of
whom completed the full eight sessions.16 At initial assess-
ment, 95% of the sample met diagnostic criteria for a
depressive disorder, with a high group mean score
(34.48, SD 9.84) on the Moods and Feelings
Questionnaire (MFQ). Post-treatment, this figure had
fallen to 22% with the group mean score on the MFQ
falling significantly below clinical cut-off (20.32, SD
11.75). These gains were maintained at 3-month
follow-up. While computer-based approaches have
demonstrated positive results for adolescents with anxiety
(eg, Coolteens17; BRAVE18), there are as yet no trials of
computerised CBT for adolescents with depression.
The use of CCBT to treat depression is therefore a
potentially effective and efficient way of enhancing
access to psychological therapies in an adolescent popu-
lation. However, this is an unevaluated technology. Since
there is a paucity of published research evidence on the
use of CCBT for adolescent depression, a feasibility
study is required to establish: the willingness of clinicians
to recruit participants and the willingness of participants
to be randomised; the acceptability and utility of a range
of outcome measures; recruitment rates; attrition rates
and an estimation of sample size needed for a fully
powered RCT. We also explored the acceptability of
CCBT to adolescents, including their satisfaction and
compliance with the programme and venue.
This feasibility study is necessary preparatory work for
a fully powered definitive RCT and will produce import-
ant research evidence to inform the care of young
people in the UK NHS.
METHODS AND ANALYSIS
Participants and recruitment
Our target population is 12–18-year-olds with low mood.
Currently in our local CAMHS patch (York and Selby)
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all referrals go through a sectorised primary mental
health worker (PMHW) system, with 8 PMHWs covering
2–3 secondary schools, all the feeder primary schools
and local General Practitioner (GP) surgeries. Referrals
can be made by any professional in contact with chil-
dren and young people (eg, teacher, GP, paediatrician,
social worker, etc). We also take referrals from a young
persons drop in centre run by the local authority, situ-
ated in the centre of York, often accessed by young
people who are out of school. Currently therefore,
young people out of school with low mood are referred
by these professionals. While we cannot guarantee that
all such young people reach our service, it is set up to
make it as accessible as possible. This provides a unique
opportunity to monitor and assess any young person in
our geographical area with low mood or depression.
The PMHWs will assess all young people who present
with any mood disorder referred through this system.
Any young person with a mood disorder at assessment
would usually be referred to tier 2, 3 or 4 CAMHS by the
PMHWs. During the study, young people who score 20 or
above on the MFQ (a validated screening tool for this age
group used in many research studies) will be referred to
the trial by the PMHWs. They will be given an informa-
tion leaflet with a copy for their parent/guardian and
offered a place on the trial. Full informed consent will be
obtained from young people and, where a young person
is under 16 years, their parent/guardian.
Even with this comprehensive referral system, we have
in place plans to conduct a second recruitment method
within schools if we fail to meet our recruitment targets
using the above outlined approach. Here, with informed
consent from governing bodies/head teachers and local
authority approval, we will recruit from local schools. In
this way the study recruitment will rotate through the
target schools. Children in year 7 to Upper Sixth between
the ages of 12–18 in local secondary schools will be
screened using the MFQ and recruited systematically.
The parents of all young people in year 7 to Upper
Sixth in all recruiting schools will receive an information
leaflet explaining the study to them. Participation is
entirely voluntary, children and their families wishing to
take part in the study will opt-in using the consent form
and the stamped addressed envelope provided.
Inclusion criteria
Our target population will be adolescents aged 12–18
with low mood/depression. Our inclusion threshold will
be a MFQ score of 20 or above, which has 70% sensitiv-
ity and 81% specificity for any mood disorder.19 The
cut-off for a major depressive episode is 29. We will also
include participants with either comorbid physical
illness or comorbid non-psychotic functional disorders,
such as anxiety.
Exclusion criteria
We will exclude participants who are seeking to end
their life, suffering psychotic symptoms or depressed in
the postnatal period. Participants with previous depres-
sion or previous treatment with antidepressants or
experience of cognitive therapy will not be excluded. We
will exclude cases of psychotic depression, since compu-
terised therapy for this group is not recommended
within NICE guidance.20
Study design
The study will be conducted between June 2011 and
December 2014. We will use a RCT methodology with
remote randomisation (provided by York Clinical Trials
Unit at the University of York). Participants who meet
our pragmatic inclusion criteria and who score 20 or
above on the MFQ will be consented into the trial and
will be asked to provide demographic information and
complete:
1. The short Beck Depression Inventory (BDI)
2. The MFQ
3. The Spence Children’s Anxiety Scale (SCAS)
4. A risk factor schedule
5. A Quality of Life and Resource Use questionnaire
Consented participants will then be randomised to
either Arm 1 or Arm 2.
Intervention
Arm 1: CCBT using the program ‘Stressbusters’
Stressbusters is a CCBT package developed by a team from
Manchester, The Institute of Psychiatry, London and
Australia (combining expertise in CBT and computer-
based delivery).
The Stressbusters software application consists of eight
30–45 min sessions of CCBT designed for 12–18 year
olds. The programme is based on the manualised treat-
ment programme from an RCT designed to evaluate
effectiveness of CBT compared to a placebo control.21
Each Stressbusters session is an interactive presentation
featuring narration synchronised with videos, anima-
tions, graphics and printouts.
The programme has a narrator guiding participants
through eight sessions in linear progression, with each
building on the knowledge gained in previous sessions
and on the tasks carried out at home. A session or part
of a session can be repeated wherever necessary.
Sessions contain flexible ‘add-ons’ such as written fact
sheets (eg, about bullying, sleep problems) which can
be printed out and taken away, together with home prac-
tice related handouts from the programme (eg, mood
diary sheets).
The video inserts (case vignettes) are of three teen-
agers who feature throughout. They are student actors
who play the roles of depressed teenagers, specially
scripted and created for the project. Participants hear
about the lives of the teenagers and watch them using
the programme in a combination of short video
sequences and voiceovers.
The session content is organised into the following
format:
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Session 1: Introduction to the programme and goal
setting
Session 2: Getting activated
Session 3: Emotional recognition
Session 4: Noticing thoughts
Session 5: Thought challenging
Session 6: Problem solving
Session 7: Improving social skills
Session 8: Relapse prevention
Arm 2: websites
This involves equivalent time to access selected websites
chosen by an expert clinical panel containing general
safe and official information on low mood/depression
and self-help. The selected websites are:
http://www.youngminds.org.uk
http://www.RU-OK.org.uk
http://www.youthhealthtalk.org
http://www.depressioninteenagers.com/
All participants will also be asked to complete the
MFQ and BDI questionnaires at 4 months and 1 year
after completion of/withdrawal from trial sessions. We
will test the feasibility of using a likert scale to explore
treatment preference as this could be used as a measure
in a fully powered trial.
Outside the trial most young people referred with low
mood/depression would usually be offered appropriate
treatment based on their symptomatology and severity.
This would most likely include face-to-face CBT, family
therapy, medication and in some instances admission to
hospital. This is a pragmatic trial and no participants
will be denied access to additional treatments and ser-
vices (offered under routine NHS care) by virtue of par-
ticipating in this trial. Both arms in the trial will also
receive care as usual and this could include any of the
following. These will be monitored and recorded for
each participant:
▸ Local counselling services (eg, youth enquiry and
support services; tier 1).
▸ Primary mental health worker support (tier 1).
▸ Individual supportive therapy or brief psychosocial
interventions (tier 2).
▸ Individual CBT (tier 2).
▸ Psychiatric referral (tier 2).
▸ Family therapy (tier 3).
▸ Group work for self-harm or depression (tier 3).
▸ In-patient admission (tier 4).
▸ Medication (while medication is not currently recom-
mended in this group, we will monitor whether any
professional prescribes).
Procedure
Participants in the CCBT group will complete eight ses-
sions of the Stressbusters programme lasting approxi-
mately 45 min (with homework between sessions) at a
private and user-friendly location. Participants using self-
help websites on low mood will be offered equivalent
time to access the websites in the same settings.
Participants will be given a choice of setting to partici-
pate including CAMH clinic sites, schools, a GP surgery
or a local community centre. A member of the research
team will meet all participants at each of their sessions
to provide them with instructions. During the sessions
the researcher will wait outside of the room where the
session takes place but will remain in close proximity to
assist participants if they have any difficulties and answer
any questions.
It will be explained to all participants that care as
usual will be available to them. For example each school
and primary care practice will have a primary mental
health worker (PMHW) who will liaise to ensure that
any professional who has concerns about any young
person can discuss their concerns and make a referral if
necessary. PMHWs can provide up to four sessions of
support or refer individuals on to an accessible member
of the specialist CAMHS team if necessary. They will also
provide consultation to other professionals supporting
the young people as usual where necessary (eg, school
nurses, school counsellors or mentors, school tutors,
Young People Advisory Service workers and other rele-
vant professionals). PMHWs will be able to access tier 2
and tier 3 professionals at any time urgently or non-
urgently in the usual way by direct referral through a
central allocation system weekly or through a daily ‘duty
clinician’ system or an urgent on call psychiatry system,
as appropriate. In this way they can be allocated to a
CAMHS professional for treatment in the usual way
either routinely or urgently at any time.
Standardised instruments will be used to trawl hospital
and mental health notes to record episodes of contact
or treatment with any CAMHS professional. The unified
NHS appointment and care tracking system will also be
used.
(The trial process is diagrammatically presented in
online supplementary appendix 1).
Outcome measures
We will examine whether CCBT affects outcome in
terms of:
Feasibility outcome measures
▸ The acceptability of a CCBT programme for
adolescents.
▸ The willingness of clinicians to recruit and young
people to be randomised.
▸ Numbers of eligible participants and recruitment
rates.
▸ Adherence to treatment and outcome measures.
▸ Time needed to collect data.
▸ The SDs of outcome measures to estimate sample size
in a fully powered RCT.
Clinical outcome measures
▸ Scores on the short BDI questionnaire (primary
outcome measure).
▸ Scores on the MFQ, the Spence Anxiety Scale, the
EQ5D-Y, the HUI2 (Health Utilities Index) and the
resource use questions. (Measures of health-related
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quality of life and resource use provide the bases to
evaluate whether cost-effectiveness would be feasible
as part of a fully powered study).
▸ Information relating to progression to further treat-
ment, episodes of self-harm and any inpatient
admissions.
Qualitative outcomes
Acceptability of the intervention and the trial process
will also be studied using a qualitative approach.
We will conduct qualitative interviews with a purpos-
ively sampled group of study participants. Based on pre-
vious research, a sample of 20 participants should be
sufficient to collect adequate data.22 The purposive sam-
pling frame will ensure maximum variation within the
qualitative sample on the basis of age, gender and
depression score. Most (15) participants will be from the
CCBT arm of the trial. A smaller number (5) of partici-
pants will be included from both withdrawals from treat-
ment and the websites group. All 20 participants will be
interviewed once after randomisation but prior to dis-
closure of allocation and again 1 week after their com-
pletion/withdrawal from the CCBT programme (or
equivalent time for those accessing self-help websites).
Qualitative interviews will be conducted using a topic
guide to ensure consistency across participants.
During the qualitative interviews, information will be
collected on topics including experiences of depression,
responses to symptoms of depression and which health
outcomes would be of the greatest value to this particu-
lar group. Data will also be collected on the trial process
itself and include questions on the acceptability of the
treatment and location, the randomisation procedure
and methods of data collection.
Qualitative interviews will be audio recorded digitally
and transcribed verbatim. Data will be managed in Atlas/
ti or NVivo 9 and will be analysed according to the con-
stant comparison method through thematic coding of
the data.23 The coding will be a combination of a priori
themes—largely relating to the acceptability of the treat-
ment and the trial process evaluation, alongside emer-
ging themes from a more in-depth analysis drawing on
theoretical models of illness behaviour in the context of
mental illness including Pescosolido’s network-episode
model24 25 and Biddle’s cycle of avoidance.26 The
primary output from the qualitative work will be data on
the acceptability of both the trial intervention and the
trial process, which will inform the design of a full-scale
trial. The qualitative interviews conducted 1 week postin-
tervention will explore participants’ views about the pro-
gramme, their satisfaction, and perceived usefulness of
the programme, their views about venue of delivery and
their experience of trial participation.
Proposed sample size
No formal power calculations are undertaken in feasibil-
ity studies; rather sufficient participants are recruited to
determine factors such as attrition and recruitment rates
in relation to feasibility outcomes.27 Thus we have based
our sample size calculations on case study work using
the Stressbusters CCBT programme in 23 young
people.16 To detect a difference of 10 points post-
treatment on the MFQ between the two groups, 80%
power and 5% significance, 26 participants per group
are required. In a previous sequential case series only 15
participants out of 28 identified (54%) completed all
eight sessions of CCBT.16 Therefore, we will need to
recruit 48 per group to account for attrition. A literature
review examining CBT for anxiety and depressive disor-
ders in children and adolescents8 found that 9 of 12 sub-
stantive studies reviewed had between 15–30 recruits in
each arm. We will therefore seek to recruit four young
people every month, over a 24-month period. Eight
PMHWs will be recruiting participants therefore each
will seek to recruit one participant every 2 months.
Given that the only previous study16 of this intervention
was a case series and not a RCT, the current study will
provide feasibility data for a definitive trial.
Data analysis
In line with recommendations about good practice in
the analysis of feasibility studies,28 analysis will be
descriptive and no statistical comparisons of the out-
comes between the two arms of the trial will be
conducted.
Descriptive statistics will be calculated for recruitment
rates, follow-up rates, attrition and adherence.
Adherence to treatment calculated will be the percent-
age in the Stressbusters group completing all eight ses-
sions, and of the website group completing all four
websites and at least four sessions.
Descriptive data will be presented for the baseline
characteristics as means and SDs or 95% CIs, medians
and IQR or percentages. Descriptive statistics will also be
calculated for the outcome measures (BDI, MFQ and
SCAS) at baseline, 4 months and 12 months follow-up,
and the change in scores from baseline. Means and SDs,
medians and IQRs will be presented. The data will be
used to develop estimates for a fully powered RCT. All
analyses will be undertaken on SPSS (V.21).
Trial status
Recruitment of participants is completed. The first par-
ticipant was enrolled in October 2011. The last partici-
pant will complete follow-up in December 2014.
ETHICS AND DISSEMINATION
Ethical and safety considerations
People with low mood/depression are vulnerable.
However, we do not anticipate any major ethical issues
with the proposed study. All adolescents will be able to
access treatment as usual and will be informed of this.
The study interventions will be in addition to this. We
do not anticipate any risks to young people through par-
ticipation. All participants will be able to access an emer-
gency duty clinician both within hours and on call and
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can access additional or alternative treatments. There
are local arrangements for urgent contact with PMHWs
between 9:00 and 17:00 on weekdays. In addition there
are CAMHS duty clinicians on a rota for urgent assess-
ments during the same hours. There is also a 24 h 7-day
per week on call service provided by a rota of consultant
psychiatrists.
Informing potential trial participants of possible benefits
and known risks
The participant information leaflets will provide poten-
tial participants with information about the possible ben-
efits and known risks of taking part in the trial.
Participants will be given the opportunity to discuss this
with either their PMHW or research coordinator prior
to consenting to participate. The research coordinator
will inform the participant if new information comes to
light that may affect their willingness to participate in
the trial.
Regarding benefits, each participant will be given a
£10 gift voucher following return of their 4-month
follow-up questionnaires as a token of gratitude for their
participation.
Obtaining informed consent from participants
Potential participants will receive an information leaflet
about the trial and one for their parent/guardian (if
under 16 years). The information leaflets will be pro-
duced using the current guidelines for researchers on
writing information sheets and consent forms.
Participants who wish to participate in the trial will sign
a consent form along with that of their parent/guardian
(if under 16 years). The researchers will then arrange a
baseline visit with them to discuss the trial, answer any
questions they may have and complete all baseline mea-
sures. Only after written consent and the completion of
baseline measures will randomisation occur.
Data protection/confidentiality
All participant information will be stored in accordance
with the Data Protection Act 1998. Participant personal
identifiable information will be stored in a locked filing
cabinet. All participant data will be anonymised by allo-
cating each participant with an ID number. Anonymised
participant data will be saved on a password-protected
secure computer drive which only members of the
research team will have access to. Participant personal
identifiable data will be stored in a separate location to
anonymised participant data. All data will be maintained
by the research coordinator.
Laptops will be purchased to enable delivery of the
CCBT and self-help websites. These laptops will be
encrypted by either IT Services within Leeds and York
partnership NHS Foundation Trust, or by purchasing
the software package Smoothwall (as recommended by
the trust), at an additional cost. This encryption will
ensure that data, including personal identifiable data,
can be stored safely on all laptops. In addition,
encrypted memory sticks will be used to transfer data
from the laptops used for intervention delivery and the
computer used by the research coordinator. All personal
data will be destroyed 6 months after the study ends and
all study data will be destroyed after 10 years.
Research governance and the conduct of the trial
The trial will be conducted to protect the human rights
and dignity of the participant as reflected in the 1996
version of the Helsinki Declaration. Participants will not
receive any financial inducement to participate. In
order to protect the trial participants the following will
apply:
▸ the trial has been designed to minimise pain, discom-
fort and fear;
▸ the trial has been designed to minimise any foresee-
able risk in relation to the treatments involved;
▸ the explicit wishes of the participants will be
respected including the right to withdraw from the
trial at any time;
▸ the interest of the patient will prevail over those of
science and society;
▸ provision will be made for indemnity by the investiga-
tor and sponsor;
▸ contact details for further information will be
provided.
Dissemination of research findings
We recognise that successful dissemination requires a
preplanned strategy that considers the groups who need
to be aware of the results of the review and the methods
with which to communicate with these groups.
Therefore, we will begin to consider our dissemination
strategy at an early stage of the project and consult
patient and public involvement (PPI) representatives
throughout all dissemination processes. Our PPI repre-
sentatives will particularly be consulted in relation to
characteristics of the audience to be targeted, appropri-
ate communication channels and the wider working
environment of our audiences.
Throughout the trial, newsletters will be produced
and forwarded to professionals within our CAMH
service to promote the trial and provide updates on its
progress. Furthermore all study findings will be dissemi-
nated through various channels. The main outcomes
and study findings of this research will be disseminated
via publication in a range of peer-reviewed journals.
Presentations of study findings will also be taken to rele-
vant research conferences, local research symposiums
and seminars for CAMHS professionals, while a short
summary of the results will be distributed to all trial par-
ticipants. Other professionals including GPs and tea-
chers will also be informed of study findings and their
implications for patient care.
Clinical trials authorisation and ethical approval
No new pharmaceutical compounds are used in this trial
and clinical trials authorisation is not required.
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Trial sponsorship
The trial is sponsored by Leeds and York Partnership
NHS Foundation Trust.
Monitoring adverse events
Inherent in the nature of the condition under scrutiny
(depression) is the risk of suicide and deliberate self-
harm. We will follow good clinical practice in monitoring
for suicide risk during all patient encounters with trial
participants. Where any risk to young people due to
expressed thoughts of self-harm is encountered, these
will be notified to the PMHW who will either contact the
participant to assess the situation or arrange for an
urgent appointment with the daily ‘duty clinician’ cover-
ing urgent calls or the on call psychiatrist (there is a
consultant psychiatrist on call at all times). We will also
collect session by session outcome measures using the
Short Mood and Feelings Questionnaire that includes a
question (‘I thought about killing myself’) which screens
for suicidal ideation. Any young person answering this
question in the affirmative will be offered an appoint-
ment urgently by their key worker (clinician or PMHW)
or the trial principal investigator if their key worker is
unavailable.
Serious adverse events that are fatal or life-threatening
will be recorded and reported to the research ethics
committee within 7 days of knowledge of such cases. All
other suspected serious unexpected adverse reactions
will be reported to the Data Monitoring Ethics
Committee (DMEC), Trial Steering Committee (TSC),
trial sponsor and ethics committee within 15 days of first
knowledge.
Trial Steering Committee
A TSC will be set up and will include an independent
chair and at least two other independent members,
along with the lead investigator and the other study col-
laborators. They will meet three times a year.
Data Monitoring Ethics Committee
A DMEC will be set up and include an independent
chair and at least two independent members. Issues sur-
rounding data collection, ethical issues and any reported
serious adverse events will be considered here. The
DMEC will meet annually.
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